Intellia Therapeutics (NASDAQ: NTLA) reported Q4 EPS of ($1.40), $0.02 worse than the analyst estimate of ($1.38). Revenue for the quarter came in at $13.6 million versus the consensus estimate of $11.17 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.